Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

IC 2011-02

Opsoclonus myoclonus syndrome/dancing eye syndrome (oms/des) in children with and without neuroblastoma (nbpos and nbneg)opsoclonus myoclonus syndrome/dancing eye syndrome (oms/des) in children with and without neuroblastoma (nbpos and nbneg)
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT01868269
Recrutement fermé
Dernière modification : 2025/02/02
Type de recherche

Interventionnel

Médicament expérimental

PHASE3


Population cible

Condition médicale (spécialité visée)

Donnée non disponible

Profil des participants

Sexe(s) des participants

ALL

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

* Children with newly diagnosed OMS/DES either NB-pos or NB-neg.

Three out of the following four components are necessary for the diagnosis of OMS/DES:

* Opsoclonus or ocular flutter (but not nystagmus)
* Ataxia and/or myoclonus
* Behavioural change and/or sleep disturbance
* Neuroblastoma The diagnosis of OMS/DES may be difficult in some patients. Opsoclonus, in particular, may be intermittent or late in onset. A video example will be available at www.dancingeyes.org.uk. If uncertain, please contact the national coordinator for support in interpreting clinical features.

* Age 6 months or over up to less than 8 years (\< 8th birthday) The date of diagnosis of OMS/DES is the date on which a doctor confirms the condition to be OMS/DES. The date of symptom onset needs also to be documented.
* Treatment start with the standard corticosteroid treatment with dexamethasone pulses as proposed by the guidelines given in this trial protocol (see 11.10, page 71).
* In patients with presumed NB-neg OMS/DES, neuroblastoma must be excluded according the guidelines of this trial (see chapter 4.4.1.4, page 30, and appendix 11.9, page 70)
* Documented informed consent for treatment and enrolment in the trial by parents / legal representatives.

Exclusion Criteria:

•Patients with opsoclonus, myoclonus or ataxia caused by other identified disease (e.g. current active CNS infection, neurometabolic disorder or demyelination).

An identified viral precursor is not an exclusion criterion.

* prior or parallel use of chemotherapy (other than required for treatment of the neuroblastoma)
* Corticoid steroid for OMS/DES or other reasons lasting 14 days or more immediately before treatment start according the standard treatment proposed (treatment with corticosteroids for less than 14 days will be allowed)
* contre-indication of use of one of the experimental study drug (cf Summary of Product Characteristics used in this study)

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Dexamethasone Cyclophosphamide Rituximab Donnée non disponible Donnée non disponible
  • Inconnu
  • Dexamethasone Cyclophosphamide Rituximab
    État du recrutement
    unknown
    Données à jour depuis : 2 février 2025

    Description de l'étude

    Résumé de l'étude

    The OMS/DES study is a multinational European Trial for Children with the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome.

    This trial brought on the way by specialists of the EPNS (European Paediatric Neurology Society), the GPOH (Gesellschaft für Pädiatrische Hematologic und Oncologie) and the SIOPEN (SIOP (International Society Oncology Pediatric) Europe Neuroblastoma).

    This protocol will investigate an escalating treatment schedule starting with a corticosteroid standard treatment with dexamethasone pulses (first step), which is followed, if response has been inadequate after 3 months of treatment, by the addition of CP (second step) and, if still no sufficient improvement, by the replacement of CP by Rituximab (third step). Treatment intensification is decided on the basis of standardized scoring of OMS/DES severity.

    Source : Importé depuis le centre

    Sites

    Centres participants

      10 affichés sur 36 centres
    • CENTRE LEON BERARD CENTRE REGIONAL DE LUTTE CONTRE LE CANCER RHONE ALPES

      Lyon

      RHÔNE, FRANCE

      Recrutement local
      État du recrutement: FERMÉ
    • CENTRE OSCAR LAMBRET

      Lille

      CEDEX B.P 307, FRANCE

      Recrutement local
      État du recrutement: FERMÉ
    • CH TROUSSEAU

      Paris

      PARIS CEDEX 12, FRANCE

      Recrutement local
      État du recrutement: FERMÉ
    • CHR DE NANTES; SERVICE D'ONCOLOGIE PEDIATRIQUE

      Nantes

      NANTES CEDEX01, FRANCE

      Recrutement local
      État du recrutement: FERMÉ
    • CHR PELLEGRIN

      Bordeaux

      FRANCE

      Recrutement local
      État du recrutement: FERMÉ
    • CHU AMIENS PICARDIE - HOPITAL SUD

      Amiens

      PICARDIE, FRANCE

      Recrutement local
      État du recrutement: FERMÉ
    • CHU ANGERS ( SITE 1313)

      Angers

      MAINE-ET-LOIRE, FRANCE

      Recrutement local
      État du recrutement: FERMÉ
    • CHU CAEN SERVICE DE PNEUMOLOGIE ( SITE 0804)

      Caen

      CALVADOS, FRANCE

      Recrutement local
      État du recrutement: FERMÉ
    • CHU D'ESTAING

      Clermont-ferrand

      CEDEX 1, FRANCE

      Recrutement local
      État du recrutement: FERMÉ
    • CHU DE BICETRE

      Paris

      MAINE ET LOIRE, FRANCE

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 2 février 2025
    Données à jour depuis : 4 fév.
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT01868269